PASylation: the Biological Alternative to PEGylation
Conference Recording Jun 03, 2013
About the SpeakerUli Binder studied molecular biotechnology and business administration. He did his Ph.D. studies at the Technische Universität München and has extensive experience in protein engineering.
Short plasma half-life is a major draw-back of most biopharmaceuticals, in particular small proteins and peptides, which can only in few cases be alleviated using depot formulations. Instead, PEGylation of biologics is now widely applied, but has disadvantages with regard to high production cost and tissue accumulation. We have developed PASylation, that is the genetic fusion of a biologic with a voluminous hydrophilic polypeptide composed of Pro, Ala, and/or Ser, as an efficient alternative technology to retard kidney filtration and design better drugs with prolonged action.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018